The present and future of measurable residual disease testing in acute myeloid leukemia
Considerable progress has been made in the past several years in the scientific understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement of a conventional remission, evaluated cytomorphologically via small bone marrow samples, is a necessary but not sufficient step...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Ferrata Storti Foundation
2022-12-01
|
| Seri Bilgileri: | Haematologica |
| Online Erişim: | https://haematologica.org/article/view/10873 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|